Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02253654 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Phase 4 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 4
- Development phase
- 216
- Enrollment target
NCT02253654 is a Phase 4 study that has completed, run by Amgen. The registered enrollment target is 216 participants.
The verdict
NCT02253654, a Phase 4 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 216 participants
- Enrollment target
Study Summary
The purpose of this study is to compare two different dosing methods of epoetin alfa and their effectiveness in maintaining hemoglobin levels between 10.0 to 11.0 g/dL in in patients with chronic kidney disease (CKD) receiving hemodialysis.
Interventions
- DRUG Epoetin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2015-04-01 |
| Est. Completion | 2016-05-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02253654
The ClinicalTrials.gov registry entry for NCT02253654 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Epoetin alfa is the first listed.
NCT02253654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02253654 about?
NCT02253654 is a clinical study titled "Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis". The purpose of this study is to compare two different dosing methods of epoetin alfa and their effectiveness in maintaining hemoglobin levels between 10.0 to 11.0 g/dL in in patients with chronic kidney disease (CKD) receiving hemodialysis.
What is the current status of trial NCT02253654?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 216 participants. The study started on 2015-04-01. Estimated completion is 2016-05-25.
What interventions are being tested in trial NCT02253654?
The interventions under investigation include: Epoetin alfa (DRUG).
Who is sponsoring clinical trial NCT02253654?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.